License Agreements and Services Agreement with Ionis (Tables)

6 Months Ended

Jun. 30, 2020

Schedule Of Net Loss Share Related to Commercial Activities Under TTR Agreement

A summary of the loss share related to the commercial activities under the TTR License Agreement is as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Net losses incurred by the collaboration related to the commercial activities under the TTR License Agreement	$	(5,922	)	$	(19,109	)	$	(17,724	)	$	(34,207	)
Ionis' share of commercial losses under the TTR License Agreement reflected in our condensed consolidated statement of operations		(3,448	)		(11,465	)		(10,499	)		(20,521	)
Akcea's share of commercial losses under the TTR License Agreement reflected in our condensed consolidated statement of operations	$	(2,474	)	$	(7,644	)	$	(7,225	)	$	(13,686	)

Schedule Of Development Expenses Related to TTR Agreement

A summary of the development expenses related to the TTR Agreement is as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Total development expense incurred by the collaboration related to development activities under the TTR License Agreement	$	(18,185	)	$	(12,032	)	$	(36,516	)	$	(26,412	)
Akcea's share of TTR development expense reflected in research and development expense in our condensed consolidated statement of operations	$	(8,290	)	$	(5,265	)	$	(16,480	)	$	(11,398	)

Amounts Recorded Related to Transactions with Ionis Including Amounts Related to TTR Licensing Transaction

The following table summarizes the amounts recorded related to transactions with Ionis including amounts related to the TTR License Agreement for the following periods (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Operating expenses:
Services performed by Ionis	$	1,903		$	1,075		$	3,806		$	2,150
Active pharmaceutical ingredient manufactured by Ionis		7,571			—			7,571			—
Sublicensing expenses		—			3,000			—			78,000
Out-of-pocket expenses paid by Ionis		1,453			1,275			2,038			2,846
Royalty expense		613			—			1,417			—
Less: commercial share of loss in connection with the TTR license transaction		(3,183	)		(11,465	)		(10,081	)		(20,521	)
Less: R&D share of loss in connection with the TTR license transaction		2,243			1,204			3,417			408
Total operating expenses (income) generated by transactions with Ionis		10,600			(4,911	)		8,168			62,883
Plus: distribution to Ionis		—			—			—			13,492
Total net charges generated by transactions with Ionis		10,600			(4,911	)		8,168			76,375
(Receivable) payable balance (from) to Ionis at the beginning of the period		(2,432	)		(7,206	)		(3,231	)		18,901
Less: total amounts received from (paid to) Ionis during the period		2,432			4,206			5,663			(28,187	)
Less: receivable from Ionis		(5,280	)		—			(5,280	)		—
Less: non-cash sublicensing expenses		—			—			—			(75,000	)
Total amount payable (receivable) to (from) Ionis at period end	$	5,320		$	(7,911	)	$	5,320		$	(7,911	)

AKCEA THERAPEUTICS, INC. 10-Q